How the ubiquitous GPCR receptor family selectively activates signalling pathways

Capper, Michael J.; Wacker, Daniel

doi:10.1038/d41586-018-05503-4

NEWS AND VIEWS
27 June 2018

How the ubiquitous GPCR receptor family selectively activates signalling pathways

G-protein-coupled receptors activate different G-protein types to trigger divergent signalling pathways. Four structures of receptor–G-protein complexes shed light on this selectivity.

Michael J. Capper ⁰ &
Daniel Wacker ¹

Michael J. Capper
1. Michael J. Capper is in the Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.
View author publications

You can also search for this author in PubMed Google Scholar
Daniel Wacker
1. Daniel Wacker is in the Department of Pharmacological Sciences and the Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.
View author publications

You can also search for this author in PubMed Google Scholar

Access through your institution

Buy or subscribe

About one-third of all drugs, including opioid painkillers, antihistamines and many antipsychotics, target members of a family of proteins called G-protein-coupled receptors (GPCRs)¹. This reflects the fact that GPCRs are important in almost all aspects of human physiology, and suggests that many more of them will be promising drug targets for numerous diseases. GPCRs span the cell membrane and convert myriad extracellular signals, including neurotransmitter molecules, hormones, and even light, into a cellular response by activating cellular G proteins and other transducer proteins. Four papers²^–⁵ in this issue help to unravel the mystery of how GPCRs selectively activate a particular group of G proteins known as G_i/o, and provide clues that might aid the design of improved GPCR-targeting drugs.

Access options

Access through your institution

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Nature 558, 529-530 (2018)

doi: https://doi.org/10.1038/d41586-018-05503-4

References

Santos, R. et al. Nature Rev. Drug Discov. 16, 19–13 (2017).
PubMed Article Google Scholar
Koehl, A. et al. Nature 558, 547–552 (2018).
Article Google Scholar
Draper-Joyce, C. J. et al. Nature 558, 559–563 (2018).
Article Google Scholar
García-Nafría, J., Nehmé, R., Edwards, P. C. & Tate, C. G. Nature 558, 620–623 (2018).
Article Google Scholar
Kang, Y. et al. Nature 558 , 553–558 (2018).
Article Google Scholar
Milligan, G. & Kostenis, E. Br. J. Pharmacol. 147, S46–S55 (2006).
PubMed Article Google Scholar
Rasmussen, S. G. F. et al. Nature 477, 549–555 (2011).
PubMed Article Google Scholar
García-Nafría, J., Lee, Y., Bai, X., Carpenter, B. & Tate, C. G. eLife 7, e35946 (2018).
PubMed Article Google Scholar
Mahoney, J. P. & Sunahara, R. K. Curr. Opin. Struct. Biol. 41, 247–254 (2016).
Article Google Scholar
Andressen, K. W. et al. FASEB J. 32, 1059-1069 (2018).
PubMed Article Google Scholar
Gregorio, G. G. et al. Nature 547, 68–73 (2017).
PubMed Article Google Scholar
Wacker, D. et al. Cell 168, 377–389 (2017).
PubMed Article Google Scholar
Lane, J. R., May, L. T., Parton, R. G., Sexton, P. M. & Christopoulos, A. Nature Chem. Biol. 13, 929–937 (2017).
PubMed Article Google Scholar
Roth, B. L., Irwin, J. J. & Shoichet, B. K. Nature Chem. Biol. 13, 1143–1151 (2017).
PubMed Article Google Scholar